Woolsey Pharmaceuticals’ BRAVYL shows promise in Phase IIa ALS trial
BRAVYL demonstrated its ability to provide significant biomarker reduction and improved clinical outcomes.
20 June 2024
20 June 2024
BRAVYL demonstrated its ability to provide significant biomarker reduction and improved clinical outcomes.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.